AJG-22-1928 1248..1255

Ryo Seishima, MD, PhD, Koji Okabayashi, MD, Hiroki Ikeuchi, MD, PhD, Motoi Uchino, MD, PhD, Kitaro Futami, MD, PhD, Tatsuki Noguchi, MD, PhD, Hiroki Ohge, MD, PhD, Yasuhito Iseki, MD, PhD, Kazuhiro Watanabe, MD, PhD, Michio Itabashi, MD, PhD, Kinya Okamoto, MD, PhD, Yuji Toiyama, MD, PhD, Takayuki Ogino, MD, PhD, Masafumi Nakamura, MD, PhD, Kazutaka Yamada, MD, PhD, Toshifumi Wakai, MD, PhD, Yu Sato, MD, PhD, Hideaki Kimura, MD, PhD, Kenichi Takahashi, MD, PhD, Koya Hida, MD, PhD, Yusuke Kinugasa, MD, PhD, Fumio Ishida, MD, PhD, Junji Okuda, MD, PhD, Koji Daito, MD, PhD, Fumikazu Koyama, MD, PhD, Hideki Ueno, MD, PhD, Takayuki Yamamoto, MD, PhD, Seiichiro Yamamoto, MD, PhD, Tsunekazu Hanai, MD, PhD, Atsuo Maemoto, MD, PhD, Junya Arakaki, MD, PhD, Koji Komori, MD, PhD, Yoshito Akagi, MD, PhD, Dai Shida, MD, PhD, Shigeki Yamaguchi, MD, PhD, Keiji Matsuda, MD, PhD, Kiyoshi Maeda, MD, PhD, Toshihiro Noake, MD, PhD, Riichiro Nezu, MD, PhD, Shin Sasaki, MD, PhD, Junichi Hasegawa, MD, PhD, Eiji Sunami, MD, PhD, Yukihide Kanemitsu, MD, PhD, Kenji Katsumata, MD, PhD, Kei Uehara, MD, PhD, Tomomichi Kiyomatsu, MD, PhD, Takeshi Suto, MD, PhD, Shinsuke Kazama, MD, PhD, Takeshi Yamada, MD, PhD, Takenori Goi, MD, PhD, Soichiro Ishihara, MD, PhD, Yoichi Ajioka, MD, PhD and Kenichi Sugihara, MD, PhD

[1]  H. Ikeuchi,et al.  Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn’s disease , 2022, Journal of Gastroenterology.

[2]  S. Itzkowitz,et al.  Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. , 2021, Gastroenterology.

[3]  S. Weissman,et al.  Colorectal Cancer Prevention in Inflammatory Bowel Disease: A Systematic Analysis of the Overall Quality of Guideline Recommendations. , 2021, Inflammatory bowel diseases.

[4]  F. Hoentjen,et al.  Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis. , 2020, Gastroenterology.

[5]  S. Pallio,et al.  Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature , 2020, Expert review of anticancer therapy.

[6]  G. Ghitulescu,et al.  Trends in Colectomies for Colorectal Neoplasms in Ulcerative Colitis: a National Inpatient Sample Database Analysis over Two Decades , 2020, Journal of Gastrointestinal Surgery.

[7]  H. Ikeuchi,et al.  Changes in the rate of and trends in colectomy for ulcerative colitis during the era of biologics and calcineurin inhibitors based on a Japanese nationwide cohort study , 2019, Surgery Today.

[8]  M. Parkes,et al.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults , 2019, Gut.

[9]  J. Feuerstein,et al.  Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments , 2019, World journal of gastroenterology.

[10]  Y. Nishiwaki,et al.  Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014: an analysis of a nationwide survey , 2019, Journal of Gastroenterology.

[11]  J. Feuerstein,et al.  Surgery in the age of biologics , 2019, Gastroenterology report.

[12]  K. Mikami,et al.  Anorectal cancer surveillance in Crohn's disease , 2018, Journal of the anus, rectum and colon.

[13]  X. Qiu,et al.  Systematic review with meta‐analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease , 2018, Alimentary pharmacology & therapeutics.

[14]  Nima Hamidi,et al.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.

[15]  A. Hart,et al.  Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study , 2017, Gut.

[16]  C. Langner,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. , 2017, Journal of Crohn's & colitis.

[17]  P. Lakatos,et al.  The epidemiology of inflammatory bowel diseases from West to East , 2017 .

[18]  X. Qiu,et al.  Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis , 2016, Oncotarget.

[19]  H. Ikeuchi,et al.  Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan , 2016, Surgery Today.

[20]  A. O’Connor,et al.  Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis , 2015, Inflammatory bowel diseases.

[21]  L. Peyrin-Biroulet,et al.  Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  P. Munkholm,et al.  Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. , 2014, Journal of the American Medical Association (JAMA).

[23]  L. Peyrin-Biroulet,et al.  Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  P. Rutgeerts,et al.  A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease , 2012, The American Journal of Gastroenterology.

[25]  M. V. van Oijen,et al.  Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease , 2011, Gut.

[26]  Norbert Senninger,et al.  Intestinal Cancer Risk in Crohn’s Disease: A Meta-Analysis , 2011, Journal of Gastrointestinal Surgery.

[27]  J. Avorn,et al.  Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. , 2010, American journal of epidemiology.

[28]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.

[29]  A. Sapino,et al.  Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical-practice-based forecast. , 2010, Inflammation & allergy drug targets.

[30]  A. Darzi,et al.  The Risk of Cancer in Patients with Crohn’s Disease , 2007, Diseases of the colon and rectum.

[31]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[32]  M. F. William A. Bye B. Com,et al.  Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis , 2018, The American Journal of Gastroenterology.

[33]  S. Ng,et al.  Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. , 2017, Gastroenterology.